Three-Pronged attack on aggressive tumors

This study is testing a new combination treatment for people with advanced, high-grade neuroendocrine tumors (NETs) who have not yet received chemotherapy for their cancer that has spread. Up to 20 participants will receive an initial phase of chemotherapy plus an immunotherapy drug, followed by a long-term maintenance phase with the immunotherapy and a targeted drug. The goal is to see if this three-drug strategy can effectively control the cancer and is safe for patients.